Ensysce Biosciences (ENSC) vs FibroBiologics (FBLG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ensysce Biosciences is the larger company by market cap ($10.3 million vs $7.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENSC | FBLG |
|---|---|---|
| Share price | $0.527 | $1.13 |
| Market cap | $10.25M | $7.86M |
| 1-day change | +15.07% | +1.80% |
| EPS (TTM) | $-2.47 | $-5.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.75 | $9.98 |
| 52-week low | $0.23 | $0.62 |
| Distance from 52-week high | -80.84% | -88.68% |
| Analyst consensus | none | none |
| Avg. price target upside | +1465.46% | +1006.19% |
| Average volume | 14.21M | 204.44K |
| Shares outstanding | 19.46M | 6.96M |
| Employees | 8 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
ENSC vs FBLG FAQ
Which is bigger, Ensysce Biosciences or FibroBiologics?
Ensysce Biosciences (ENSC) is larger, with a market capitalization of $10.25M compared with $7.86M for FibroBiologics (FBLG).
Are Ensysce Biosciences and FibroBiologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.